Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars C Rump

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Elife|April 25, 2015
Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronismUte I Scholl, Gabriel Stölting, Carol Nelson-Williams, et al.
Journal of Human Hypertension|May 25, 2021
Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO studyManish Saxena, Roland E Schmieder, Ajay J Kirtane, et al.
Nature Genetics|February 7, 2018
CLCN2 chloride channel mutations in familial hyperaldosteronism type IIUte I Scholl, Gabriel Stölting, Julia Schewe, et al.
JACC. Cardiovascular Interventions|December 28, 2020
12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal DenervationMichel Azizi, Joost Daemen, Melvin D Lobo, et al.
Journal of the American College of Cardiology|September 12, 2013
International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertensionMarkus P Schlaich, Roland E Schmieder, George Bakris, et al.
Lancet (London, England)|May 19, 2021
Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trialMichel Azizi, Kintur Sanghvi, Manish Saxena, et al.
Journal of Thrombosis and Haemostasis : JTH|January 25, 2023
Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpuraLinus A Völker, Jessica Kaufeld, Gesa Balduin, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Elife|April 25, 2015
Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronismUte I Scholl, Gabriel Stölting, Carol Nelson-Williams, et al.
Journal of Human Hypertension|May 25, 2021
Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO studyManish Saxena, Roland E Schmieder, Ajay J Kirtane, et al.
Nature Genetics|February 7, 2018
CLCN2 chloride channel mutations in familial hyperaldosteronism type IIUte I Scholl, Gabriel Stölting, Julia Schewe, et al.
JACC. Cardiovascular Interventions|December 28, 2020
12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal DenervationMichel Azizi, Joost Daemen, Melvin D Lobo, et al.
Journal of the American College of Cardiology|September 12, 2013
International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertensionMarkus P Schlaich, Roland E Schmieder, George Bakris, et al.
Lancet (London, England)|May 19, 2021
Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trialMichel Azizi, Kintur Sanghvi, Manish Saxena, et al.
Journal of Thrombosis and Haemostasis : JTH|January 25, 2023
Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpuraLinus A Völker, Jessica Kaufeld, Gesa Balduin, et al.
Pageof 7